Depression and endocrine disorders: focus on the thyroid and adrenal system.

Depression and endocrine disorders: focus on the thyroid and adrenal system. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Depression and endocrine disorders: focus on the thyroid and adrenal system. Abstract Text:

D L Musselman,C B Nemeroff,

Of the various hypothalamic-pituitary-end organ axes, the thyroid and adrenal systems have been implicated most often in affective disorders. Patients with primary thyroid disease have high rates of depression, and patients with Addison's disease or Cushing's syndrome have relatively high rates of affective and anxiety symptoms. However, the major support for these endocrine axes in the pathophysiology of mood disorders comes from studies in which alterations in components of the hypothalamic-pituitary-thyroid (HPT) and the hypothalamic-pituitary-adrenal (HPA) axes have been documented in patients with primary depression. Concerning the HPT axis, depressed patients have been reported to have: (a) alterations in thyroid-stimulating hormone response to thyrotropin-releasing hormone (TRH); (b) an abnormally high rate of antithyroid antibodies; and (c) elevated cerebrospinal fluid (CSF) TRH concentrations. Moreover, tri-iodothyronine has been shown conclusively to augment the efficacy of various antidepressants. Concerning the HPA axis, depressed patients have been reported to exhibit: (a) adrenocorticoid hypersecretion; (b) enlarged pituitary and adrenal gland size; and (c) elevated CSF corticotropin-releasing factor concentrations. All of the HPA axis alterations in depression studied thus far are state-dependent, whereas the HPT axis alterations may be partially trait and partially state markers.

Depression and endocrine disorders: focus on the thyroid and adrenal system. Publishing Authors By Initials

DL Musselman,CB Nemeroff,

For similar hormones, hormone substitutes, and hormone antagonists: hormones: peptide hormones: hypothalamic hormones: pituitary hormone-releasing hormones: thyrotropin-releasing hormone research abstracts see: hormones, hormone substitutes, and hormone antagonists: hormones: peptide hormones: hypothalamic hormones: pituitary hormone-releasing hormones: thyrotropin-releasing hormone research

PUBMED ID PMID:

MEDLINE DATE:

Depression and endocrine disorders: focus on the thyroid and adrenal system. Journal Published:

PUBLICATION TYPE: Review

Journal: The British journal of psychiatry. Supplement

VOLUME:

Page Numbers: 123-8

Journal Abbreviation:

ISSN: 0960-5371

DAY: 22

MONTH: Jun

YEAR: 1996

Depression and endocrine disorders: focus on the thyroid and adrenal system. Information

Number of References: 73

LANGUAGE: eng

NlmUniqueID: 9001294

Depression and endocrine disorders: focus on the thyroid and adrenal system. Keywords Mesh Terms:

KEYWORDS: Thyrotropin-Releasing Hormone

MESH TERMS: physiology

Chemical & Substance for Abstract: Depression and endocrine disorders: focus on the thyroid and adrenal system. Information

Substance Name: Corticotropin-Releasing Hormone

Registry Number: 9015-71-8

Grant and Affiliation Information for Depression and endocrine disorders: focus on the thyroid and adrenal system.

AFFILIATION: Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.

Country: ENGLAND

AGENCY: United States NIMH

GRANT: MH39415

ACRONYM: MH

MEDLINETA: Br J Psychiatry Suppl

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Depression and endocrine disorders: focus on the thyroid and adrenal system Related Publications

• An interactive web-based method of outreach to college students at risk for suicide.
• CSF corticotropin releasing hormone, somatostatin, and thyrotropin releasing hormone in schizophrenia.
• Cuba II: A Land Stuck in Time.
• Cuba: a land stuck in time.
• Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy.
• Depression and endocrine disorders: focus on the thyroid and adrenal system.
• Depression, desperation, and suicidal ideation in college students: results from the American Foundation for Suicide Prevention College Screening Project at Emory University.
• Drug development for anxiety disorders: new roles for atypical antipsychotics.
• Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders.
• Effect of desipramine on cerebrospinal fluid concentrations of corticotropin-releasing factor in human subjects.
• Emerging treatments for depression.
• Endogenous neurotensin is involved in estrous cycle related alterations in prepulse inhibition of the acoustic startle reflex in female rats.
• Fostering foster care outcomes: quality of intervention matters in overcoming early adversity.
• How are you?
• Involvement of neuropeptide systems in schizophrenia: human studies.
• Neuropeptides and Alzheimer's disease.
• Neurotensin: role in psychiatric and neurological diseases.
• New directions in the development of antidepressants: the interface of neurobiology and psychiatry.
• One brain, but different clinical disciplines: should psychiatry and neurology be United?
• Overview of the safety of citalopram.
• Sertraline and desmethylsertraline in human breast milk and nursing infants.
• Stress, menopause and vulnerability for psychiatric illness.
• The burden of severe depression: a review of diagnostic challenges and treatment alternatives.
• The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma.
• The interaction of serotonin transporter gene polymorphisms and early adverse life events on vulnerability for major depression.
• The neurobiology of bipolar disorder.
• The neurobiology of social anxiety disorder: the relevance of fear and anxiety.
• The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentrations.
• The role of patient advocacy in funding policy.
• Understanding the pathophysiology of postpartum depression: implications for the development of novel treatments.